Next Article in Journal
The Role of Optical Coherence Tomography in Differential Diagnosis of Multiple Sclerosis and Autoimmune Connective Tissue Diseases with CNS Involvement
Previous Article in Journal
Do Centenarians Die Healthier than Younger Elders? A Comparative Epidemiological Study in Spain
Open AccessReview

Heme Oxygenase-1 in Central Nervous System Malignancies

1
Department of Drug Science, Biochemistry Section, University of Catania, Viale A. Doria 6, 95125 Catania, Italy
2
Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia, 97 95125 Catania, Italy
3
Department of Biochemical Sciences “A. Rossi-Fanelli”, Sapienza University of Rome, Piazzale A. Moro 5, 00185 Roma, Italy
4
EuroMediterranean Institute of Science and Technology, Via Michele Miraglia 20, 90139 Palermo, Italy
*
Authors to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(5), 1562; https://doi.org/10.3390/jcm9051562
Received: 21 March 2020 / Revised: 23 April 2020 / Accepted: 20 May 2020 / Published: 21 May 2020
(This article belongs to the Section Oncology)
Central nervous system tumors are the most common pediatric solid tumors and account for 20–25% of all childhood malignancies. Several lines of evidence suggest that brain tumors show altered redox homeostasis that triggers the activation of various survival pathways, leading to disease progression and chemoresistance. Among these pathways, heme oxygenase-1 (HO-1) plays an important role. HO-1 catalyzes the enzymatic degradation of heme with the simultaneous release of carbon monoxide (CO), ferrous iron (Fe2+), and biliverdin. The biological effects of HO-1 in tumor cells have been shown to be cell-specific since, in some tumors, its upregulation promotes cell cycle arrest and cellular death, whereas, in other neoplasms, it is associated with tumor survival and progression. This review focuses on the role of HO-1 in central nervous system malignancies and the possibility of exploiting such a target to improve the outcome of well-established therapeutic regimens. Finally, several studies show that HO-1 overexpression is involved in the development and resistance of brain tumors to chemotherapy and radiotherapy, suggesting the use of HO-1 as an innovative therapeutic target to overcome drug resistance. The following keywords were used to search the literature related to this topic: nuclear factor erythroid 2 p45-related factor 2, heme oxygenase, neuroblastoma, medulloblastoma, meningioma, astrocytoma, oligodendroglioma, glioblastoma multiforme, and gliomas. View Full-Text
Keywords: nuclear factor erythroid 2 p45-related factor 2; NRF2; ROS; brain cancer; oxidative stress nuclear factor erythroid 2 p45-related factor 2; NRF2; ROS; brain cancer; oxidative stress
Show Figures

Figure 1

MDPI and ACS Style

Sferrazzo, G.; Di Rosa, M.; Barone, E.; Li Volti, G.; Musso, N.; Tibullo, D.; Barbagallo, I. Heme Oxygenase-1 in Central Nervous System Malignancies. J. Clin. Med. 2020, 9, 1562.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop